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Summary The efficacy and safety of the fixed combi-
nation of cinnarizine 20 mg and dimenhydrinate 40 mg 
in the treatment of vertigo of various origins have been 
investigated in a prospective, noninterventional study 
involving private practices throughout Germany. A total 
of 1275 patients with an average age of 61.2 years par-
ticipated in the study. The vertigo symptoms, measured 
by a validated mean vertigo score (primary efficacy 
endpoint) improved by 61 % in the course of the obser-
vational period (median: 6 weeks). Concomitant symp-
toms frequently associated with vertigo such as nausea, 
vomiting and tinnitus were also markedly reduced by 84, 
85 and 51 %, respectively. Overall efficacy has been rated 
by the physicians as ‘very much improved’ or ‘much 
improved’ in 95 % of the patients. A total of 47 patients 
(3.7 %) reported 51 adverse drug reactions (all nonseri-
ous). The results indicate a good tolerability and efficacy 
of the fixed combination of cinnarizine and dimenhydri-
nate in the treatment of vertigo in daily medical practice, 
which is in line with previous findings of numerous inter-
ventional, randomised, double-blind, controlled clinical 
trials.
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Introduction
Vertigo is one of the most common complaints reported 
in daily medical practice [1, 2], with a general prevalence 
of 17–32 %, among the population over 80 years up to 
39 % [3]. The prevalence of vertigo increases with age [4, 
5] resulting in a steady rise in incidence due to the global 
rise in general life expectancy. Especially in the elderly, 
vertigo is commonly associated with significant morbid-
ity and even immobilisation or chronic invalidism, espe-
cially when aggravated by falls and resulting injury [6, 7]. 
In general, vertigo can impose considerable limitations 
on the patients’ ability to cope with daily activities, lead-
ing to a self-perceived reduction in the quality of life [4, 
8] Therefore, the availability of an effective antivertigo 
treatment is of particular importance in medical prac-
tice, both to provide instant relief to the affected patients 
and for pharmacoeconomic reasons.
As vertigo may be associated with a wide range of 
underlying disorders, it constitutes a particular challenge 
in both primary and secondary care. In many cases, sub-
jective vertigo symptoms can hardly be unambiguously 
attributed to a defined organic correlate, often leading 
to rather unspecified diagnoses. In particular, general 
practitioners (GPs) require an effective vertigo treatment 
option without having direct access to sophisticated 
diagnostic equipment needed for detailed diagnostics, 
especially in elderly patients with a high number of com-
plex comorbidities.
The fixed combination of cinnarizine 20  mg and 
dimenhydrinate 40 mg (Arlevert®, Hennig Arzneimittel, 
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Floersheim am Main, Germany) has been successfully 
used in the treatment of vertigo of various origins for 
more than three decades. Its efficacy is based on a dual 
mechanism of action, with the specific calcium channel 
blocker cinnarizine acting predominantly on the periph-
eral vestibular system and the antihistamine dimenhy-
drinate acting predominantly on the central vestibular 
system. The efficacy and safety of the combination prepa-
ration has been demonstrated in numerous randomised, 
double-blind, controlled clinical trials comprising a vari-
ety of patient populations [9–17]. The present noninter-
ventional study was undertaken to determine whether 
the good efficacy and tolerability of the fixed-combina-
tion preparation reported in controlled clinical trials can 
be reproduced in routine clinical practice, which in turn 
provides deeper insight into the product’s effectiveness 
and safety when used in larger patient collectives.
Patients, materials and methods
This prospective, open-label, noninterventional study has 
been carried out in primary and secondary care private 
practices throughout Germany between January 1992 and 
August 2008. Physicians, who prescribed the commercially 
available fixed-combination preparation for the treatment 
of vertigo patients in the course of normal clinical practice, 
have been offered to document the treatment outcome on 
standardised case report forms provided by the sponsor. 
Thus, prior to the inclusion of a patient in the study, it was 
at the participating physicians own discretion to use the 
combination preparation for the treatment of patients with 
vertigo of various origins in accordance with the terms of 
the summary of product characteristics (SmPC). For the 
selection of patients, no specific requirements were in 
place regarding inclusion or exclusion criteria, apart from 
the contraindications and safety recommendations listed 
in the product information. The physicians determined 
the starting dose (recommended dosage 3 × 1, up to 5 × 1 
tablet per day), administration frequency and any later 
changes to either dose or frequency as well as the duration 
of treatment in line with the applicable German SmPC and 
independent of study documentation.
Demographic data, medical history, differential diag-
nosis and duration of vertigo, prior medical treatment, 
concomitant diseases and concomitant medications 
were registered on the occasion of the first visit. Patients 
rated the intensity of vertigo and concomitant symptoms 
(see below) by means of a 5-point verbal rating (or visual 
analogue) scale ranging from no vertigo (0) to slight (1), 
medium (2), strong (3) and very strong (4), both at the 
beginning (baseline) and at the end of the observational 
period. For approximately one third of the study partici-
pants, additional data were registered on the occasion 
of an interim visit after approximately 2 weeks. Fur-
thermore, the physician assessed the overall (‘global’) 
efficacy by means of a 5-point verbal rating scale from 
very much improved (4) to much improved (3), slightly 
improved (2), not improved (1) and deteriorated (0).
The change in a validated MVS between baseline and 
end of observation has been used as the primary efficacy 
endpoint. The MVS was calculated as the mean of the 
following six (unprovoked) vertigo symptoms: dysstasia 
and walking unsteadiness, staggering, rotary sensation, 
tendency to fall, lift sensation and blackout. Secondary 
efficacy endpoints included the changes in concomitant 
symptoms (nausea, vomiting, sweating, tachycardia, 
tinnitus, impaired hearing) and the physicians’ global 
judgement of efficacy. A subgroup analysis was per-
formed with respect to the type of vertigo.
The safety evaluation comprised the documentation 
of adverse events (AEs), including their classification 
with respect to seriousness, severity and possible relat-
edness to the study medication (adverse drug reaction, 
ADR). Additionally, the tolerability of the treatment was 
assessed by the physician on a 4-point verbal rating scale 
(very good, good, moderate or poor) on the occasion of 
the final visit.
Due to the observational character of the study, analy-
ses were descriptive in nature. After double data entry, 
statistical analyses were performed using SAS 9.1.3 (SAS 
Institute Inc.). Assuming continuous but not necessar-
ily normal distribution of the data, the Wilcoxon signed 
rank test was used to test the changes in the intensity of 
vertigo symptoms on the 5 % significance level. In order 
to account for possible deficiencies in the distributional 
properties of the MVS, as an alternative for parametric 
analysis (based on the mean), the median was calculated 
for baseline, final visit and for the changes between the 
two visits. For the median of the changes, nonparametric 
95 % confidence intervals (CI95 %) based on order sta-
tistics are provided in addition to the parametric confi-
dence intervals for the mean (based on the t-test model). 
Statistical analysis was performed using the intent-to-
treat data set (safety population), including all patients 
who had been enrolled in the study. Missing data were 
imputed conservatively, that is values missing at base-
line and at the end of observation were replaced by the 
best and the worst corresponding value of a patient in the 
sample, respectively. In addition, all analyses were per-
formed on the basis of all available data without imput-
ing missing values (‘data as available’) in order to check 
the robustness of the results.
Results
Overall, 443 private practices throughout Germany par-
ticipated in this observational study and contributed data 
from a total of 1275 patients. The physicians involved in 
the study mainly comprised GPs/internal medicine spe-
cialists, otorhinolaryngologists and neurologists/psychi-
atrists (Table 1). Male (34 %) and female (66 %) patients 
aged between 15 and 99 years (mean age: 61.2 years) were 
included in the study; female patients were on average 
slightly older than male patients (for details see Table 2). 
The mean duration of vertigo before enrolment in the 
study was approximately 1 year and ranged from less 
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For 424 patients, additional data were registered 
on occasion of an interim visit after around 2 weeks of 
treatment. Only 21 patients (1.7 %) terminated the study 
prematurely, 7 because of complete remission of vertigo 
symptoms until the interim visit, 2 because of inadequate 
efficacy, 3 due to AEs and 9 for unknown reasons.
Based on 1275 patients (safety population), treatment 
with the fixed-combination preparation led to a distinct 
improvement of the MVS in the course of the observa-
tional period. The mean value of the MVS was reduced 
from 1.46 at baseline to 0.57 at the end of observation, 
corresponding to a 61 % reduction by 0.89 (CI95 %: 0.83–
0.94), whereas the median reduction from baseline was 
0.93 (CI95 %: 0.83–1.00). The reduction was statistically 
significant (Wilcoxon signed rank test: p< 0.001); for 
more details see Table 4 and Fig. 1a. A total of 282 patients 
(22.1 %) were completely symptom-free at the end of 
observation. Even after the relatively short period of 
treatment until the interim visit, a statistically significant 
mean reduction of the MVS by 0.52 (CI95 %: 0.43–0.62; 
p < 0.001) from 1.66 to 1.14 has been achieved (Fig. 1b), 
with a median reduction from baseline of 0.57 (CI95 %: 
0.50–0.62).
The single vertigo symptoms most often reported as 
‘severe’ or ‘very severe’ prior to the treatment were rotary 
than 1 month to up to 20 years (Table 2). Nearly one third 
of the patients had taken antivertigo drugs before inclu-
sion in the study. The most commonly used drugs were a 
homeopathic combination preparation, betahistine and 
Ginkgo biloba (Table 3). It can be assumed that in most 
cases the prior medical treatment had been discontinued 
because of insufficient effectiveness, and for this reason 
it was replaced by the combination preparation.
For 799 patients (62.7 %), 1476 concomitant diseases 
have been documented, the most frequent of which were 
essential (primary) hypertension (n = 289), chronic isch-
aemic heart disease (n = 136), unspecified diabetes melli-
tus (n = 95) and disorders of lipoprotein metabolism and 
other lipidaemias (n = 71). A total of 603 patients (47.3 %) 
had received 1206 concomitant medications; ACE inhibi-
tors (plain: n = 96, combinations: n = 21), beta blocking 
agents (n = 102), analgesics and antipyretics (n = 88), 
blood glucose lowering drugs excluding insulin (n = 87), 
vasodilators used in cardiac diseases (n = 83) and lipid-
modifying agents (n = 61) were the most frequently pre-
scribed drugs.
The vast majority of study participants had been pre-
scribed either the standard dosage of 3 × 1 tablet per 
day of the fixed combination (89.1 % of the patients) or 
a reduced dosage of 2 × 1 tablet per day (8.6 %). For 110 
patients, a change of the dosage in the course of the 
treatment has been reported, with a dose increase in 27 
patients and a dose reduction in 83 patients. The aver-
age duration of treatment was 8.4 ± 1.5 weeks, with a 
broad range of between less than 1 week and 162 weeks 
(median: 6 weeks).
Table 1 Distribution of patients (n = 1275) among the medi-
cal disciplines participating in the study
Medical discipline Number of patients %
GPs/internal medicine specialists 729 57.2
Otorhinolaryngologists 419 32.9
Neurologists/psychiatrists 121 9.5
Others (e.g. surgeons) 6 0.4
Table 2 Selected demographic data and other baseline characteristics (safety population; n = 1275): number (n) and percent-
age (%) of patients, mean value of the respective parameter (Mean), standard deviation (SD) and range (minimum (Min), median 
(Med) maximum (Max))
Parameter Patients Statistical data
na % Mean SD Range
Min Med Max
Age (years) 1272 61.2 15.5 15 63 99
Male 433 34 59.4 14.7 15 61 93
Female 837 66 62.1 15.7 19 64 99
Height (cm) 1238 167.9 8.1 146 168 193
Weight (kg)] 1236 73.0 11.5 39 72 120
BMI (kg/m2) 1236 25.9 3.5 14.7 25.7 42.2
Duration of vertigo 
(months)
1189 12.3 23.1 < 1 3 240
aData not available for all enrolled patients
Table 3 Antivertigo drug treatment before enrolment in the 
study: a total of 400 drugs were documented in 375 of 1275 
patients (29.4 %); number (n) and percentage (%) of patients
Antivertigo drug n %
Homeopathic combination 114 28.50
Betahistine 95 23.75
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decreased from 0.85 ± 0.80 to 0.37 ± 0.69, corresponding 
to a significant reduction by 56.5 % (0.48 ± 0.99; CI95 %: 
0.42–0.53; p < 0.001). During the interim visit (n = 424), 
the reduction of the vegetative symptoms by 30.8 % 
(0.32 ± 0.96; CI95 %: 0.23–0.41) was already statistically 
significant (p < 0.001).
Nausea and vomiting in particular, both frequently 
associated with vertigo, improved by 84 % and 85 %, 
respectively in the course of treatment. At baseline, 
nausea was reported by 832 (65.3 %) of all the patients. 
The mean value decreased from 1.25 ± 1.16 to 0.20 ± 0.44 
(Fig.  2), which corresponds to a reduction by 84 % 
(1.05 ± 1.07; CI95 %: 0.14–0.26). Regarding only those 227 
patients who described either ‘severe’ (n = 165) or ‘very 
severe’ (n = 62) nausea at baseline, 197 (86.8 %) reported 
sensation (43.7 %), dysstasia and walking unsteadiness 
(37.1 %) and staggering (30.6 %). At the end of observa-
tion, these symptoms were either disappeared or rated as 
‘mild’ by 78.4 %, 64.6 %, respectively 69.0 % of the same 
patients.
Vertigo of peripheral or combined central-peripheral 
origin had been diagnosed in more than half of the study 
participants, whereas the type of vertigo could not be 
specified in 28 % of the patients. With respect to each type 
of vertigo, the reduction of the MVS was statistically sig-
nificant (Wilcoxon signed rank test: p < 0.001); the mean 
and median reductions from baseline together with their 
95 % CI are given in Table 4.
The mean score of the four vegetative concomitant 
symptoms nausea, vomiting, sweating and tachycardia 
Table 4 Reduction of the mean vertigo score (MVS) depending on type of vertigo and with respect to all patients: number (n) 
and percentage (%) of patients, mean value (Mean) with standard deviation (SD), median (Med) and 95 % confidence intervals 
(CI95 %)
Type of vertigo Patients MVS Reduction in MVS
Baseline Final visit
n % Mean (SD) Med Mean (SD) Med Mean (SD) Med CI95 %a
Mean Med


















































bData for one patient not available
Fig. 1 Reduction of the mean vertigo score (MVS (Mean 
score of six single, unprovoked vertigo symptoms (dysstasia 
and walking unsteadiness, staggering, rotary sensation, ten-
dency to fall, lift sensation and blackout)) after treatment with 
a fixed-combination preparation of cinnarizine 20 mg and di-
menhydrinate 40 mg. a Difference between baseline and end 
of observation (n = 1275). Vertigo symptoms improved signifi-
cantly (p < 0.001). Approximately, 22% of the patients have 
been completely symptom-free at the end of observation. b 
Difference between baseline and interim visit (n = 424). Vertigo 
symptoms already improved significantly (p < 0.001) after ap-
proximately 2 weeks of treatment
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ised as nonserious and the majority was of mild (45.1 %) 
or moderate (23.5 %) intensity. Moreover, the fixed-com-
bination preparation did not show a clinically relevant 
effect on blood pressure. The physician’s assessment of 
tolerability of the treatment by means of a 4-point verbal 
rating scale was as follows: ‘very good’ in 843 (68.5 %), 
‘good’ in 366 (29.7 %), ‘moderate’ in 15 (1.2 %) and ‘poor’ 
in 7 (0.6 %) out of 1231 patients.
Discussion
The present noninterventional study shows that the 
low-dose fixed combination of cinnarizine and dimen-
hydrinate, as used under real life conditions, is effec-
tive at reducing both vertigo and frequently associated 
concomitant symptoms such as nausea and vomiting 
in patients suffering from vertigo of various origins. The 
study population largely mirrored a representative pic-
ture of patients with vertigo seen in daily medical prac-
tice. Particularly with respect to age and gender, the 
enrolled patients represented a typical vertigo popula-
tion with a mean age of 61 years; the majority of patients 
being women [18].
The complexity of the vestibular system and limited 
availability of sophisticated diagnostic equipment often 
make it difficult or even impossible to establish an exact 
diagnosis, especially within the primary and secondary 
care setting. However, vertigo can impose considerable 
limitations on the patients’ ability to cope with daily 
activities, reduce quality of life and could become chronic 
if left untreated. Therefore, the authors believe that a 
rapid and effective symptomatic treatment is not only 
acceptable but in fact can be generally recommended. 
For this purpose, the fixed combination of cinnarizine 
and dimenhydrinate is particularly suited because of its 
broad range of efficacy in the treatment of vertigo. Due to 
the dual mode of action, with cinnarizine mainly acting 
on the peripheral vestibular system and dimenhydrinate 
on the central vestibular system, the combination prepa-
ration is well established as first-line treatment of vertigo 
in Germany and numerous other countries.
The broad spectrum of patients with vestibular (cen-
tral, peripheral or combined central-peripheral) vertigo, 
as well as with vertigo of non-vestibular or unspecified 
origin included in this noninterventional study largely 
reflects the routine conditions in daily medical practice. 
Moreover, the recommended standard dosage of 3 × 1 
tablet/day of the combination preparation had been pre-
scribed to the vast majority of the patients (89 %), typi-
cally for the duration of around 6–8 weeks.
A validated composite score comprising six single ver-
tigo symptoms (MVS) was considered the most appropri-
ate approach to measure the patients’ outcome and due 
to its easy use, maximum assessment compliance could 
be expected.
Independent of the type of vertigo, treatment with 
the fixed-combination product led to a distinct over-
all reduction of vertigo symptoms by 61 %, with 22 % of 
either no (n = 118) or only ‘mild’ nausea (n = 79) at the 
end of observation.
A total of 404 patients (31.7 %) suffered from vomit-
ing at baseline. The mean value improved by 85 % from 
0.52 ± 0.91 to 0.08 ± 0.29 (reduction by 0.44 ± 0.87; CI95 %: 
0.06–0.10; Fig.  2). In those 76 patients who initially 
reported the intensity of vomiting as ‘severe’ (n = 55) or 
‘very severe’ (n = 21), the symptom was either no longer 
present (n = 52) or of only mild extent (n = 19) at the end 
of observation, which means a distinct improvement in 
93.4 % of the patients.
Tinnitus was initially reported by 666 patients (52.2 %), 
and the mean value improved by 51 % from 1.03 ± 1.21 to 
0.51 ± 0.73 (reduction by 0.52 ± 0.86; CI95 %: 0.47–0.55; 
Fig.  2). In those 213 patients who rated the intensity of 
tinnitus at baseline as ‘severe’ (n = 150) or ‘very severe’ 
(n = 63), the symptom was either no longer present 
(n = 28) or of only mild extent (n = 83) at the end of obser-
vation, corresponding to a distinct improvement in more 
than half of the patients.
On the occasion of the final consultation, the over-
all (global) efficacy was assessed by the physician using 
a 5-point verbal rating scale. After treatment with the 
fixed-combination preparation, the health condition was 
rated as either ‘very much improved’ in 40 % or ‘much 
improved’ in 45 % of the patients; ‘slightly improved’ 
and ‘not improved’ were reported for 13 and 2 % of the 
patients, respectively, whereas no deterioration of the 
health condition occurred in any patient.
In total, 58 nonserious AEs have been reported by 53 
patients (4.2 %), 51 of which were judged as ADRs by the 
physician. The majority of ADRs were classified accord-
ing to System Organ Class (SOC) (MedDRA®) as gastro-
intestinal disorders (n = 25; reported by 1.8 % of all the 
patients) or nervous system disorders (n = 15; 1.2 % of all 
the patients). The most commonly reported ADRs were 
somnolence/tiredness (n = 8), dry mouth (n = 8), nausea 
(n = 6) and headache (n = 6). All 51 ADRs were character-
Fig. 2 Reduction of the concomitant symptoms nausea, vom-
iting and tinnitus in the course of treatment with the fixed-
combination preparation of cinnarizine 20  mg and dimen-
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roborates previous findings of numerous interventional, 
randomised, double-blind, controlled clinical trials 
[9–17] and confirms their validity in a setting representa-
tive of clinical routine. Because of its dual mode of action 
and synergistic effect, with cinnarizine acting as calcium 
antagonist and dimenhydrinate as antihistamine, the 
fixed-combination product effectively reduces vertigo 
and associated symptoms caused by a great variety of 
underlying vestibular or non-vestibular disorders. Espe-
cially in the primary and secondary care setting, where 
an exact diagnosis and subsequent causal treatment is 
quite often not possible, the combination preparation 
provides immediate symptomatic relief and is therefore 
considered as first-line treatment for patients with ver-
tigo of various origins.
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